New Paragraph
LigandPro Platform
LigandPro platform identifies novel small molecule "hits" that can be built into TPD drugs. It offers an efficient and cost-effective approach to drug discovery compared to traditional biochemical High Throughput Screening (HTS). It can also serve as a complement to other experimental and in-silico methods.
Ligand Pro Platform
Key Capabilities
Unbiased Screening
LigandPro utilizes a protein agnostic approach, it doesn't rely on preconceived hypotheses about protein interactions, allowing for the identification of novel interactions
Comprehensive Polypharmocology
LigandPro generates a detailed protein-small molecule interaction map, providing valuable insights into potential drug targets and their mechanisms of action reducing the likelihood of off-target impacts
Enhanced Sensitivity
The platform's unique screening process, allows for the detection of even transient and low-affinity interactions. This sensitivity is crucial for uncovering potential drug targets that might be missed by other screening methods
Cost-Effectiveness and Speed
LigandPro is designed to utilize smaller quantities of compounds, less expensive reagents and instrumentation requirements while delivering higher throughput. In addition, by targeting any protein surface, we can reduce the need for downstream research. Through a combination of these approaches, we are able to complete screening projects in 3-6 months and at less than 50% of the cost of traditional approaches
LigandPro Benefits
Identify Novel E3 Ligase Binders, Molecular Glues and Drug Targets
Identify previously unknown protein-small molecule interactions that will lead to the development of first-in-class drugs for currently undruggable targets, E3 Ligase Binders and Molecular Glues
Accelerate Drug Discovery
Through a detailed understanding of polypharmacology and exploiting existing molecules, you can rapidly bring TPDs with better safety profiles and dosage models to clinical stages
Develop TPDs cost-effectively
Through a detailed understanding of polypharmacology and exploiting existing molecules, you can rapidly bring TPDs with better safety profiles and dosage models to clinical stages
